This regulatory status is designed for therapies targeting rare, life-threatening, or chronically debilitating diseases.
Cushing’s syndrome of endogenous origin is a rare endocrine disease caused in most instances by excessive production of adrenocorticotropic hormone (ACTH).
This is often due to a pituitary tumour known as Cushing’s disease, or less frequently ...